Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients.

Martin-Malo A, Papadimitriou M, Cruz J, Bustamante J, Verbeelen D, Nony A, Vanholder R, Jacobson SH, Montenegro J, Hannedouche T, Wizemann V, Locatelli F; Membrane Permeability Outcome (MPO) Study Group.

J Nephrol. 2013 Jan-Feb;26(1):119-28. doi: 10.5301/jn.5000116.

PMID:
22476964
2.

Novel susceptibility locus at 22q11 for diabetic nephropathy in type 1 diabetes.

Wessman M, Forsblom C, Kaunisto MA, Söderlund J, Ilonen J, Sallinen R, Hiekkalinna T, Parkkonen M, Maxwell AP, Tarnow L, Parving HH, Hadjadj S, Marre M, Peltonen L, Groop PH; FinnDiane Study Group.

PLoS One. 2011;6(9):e24053. doi: 10.1371/journal.pone.0024053. Epub 2011 Sep 1.

3.

[Membrane roughness: A relevant concept in haemodialysis].

Chanard J, Thomas M, Rieu P.

Nephrol Ther. 2010 Jun;6(3):158-61. doi: 10.1016/j.nephro.2009.10.006. Epub 2010 Mar 31. Review. French.

PMID:
20359975
4.

Evaluation of sample bias for measuring plasma iohexol clearance in kidney transplantation.

Stolz A, Hoizey G, Toupance O, Lavaud S, Vitry F, Chanard J, Rieu P.

Transplantation. 2010 Feb 27;89(4):440-5. doi: 10.1097/TP.0b013e3181ca7d1b.

PMID:
20177346
5.

Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.

Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L; French Vasculitis Study Group.

Arthritis Rheum. 2010 Feb;62(2):616-26. doi: 10.1002/art.27240.

6.

[Why and how correct calcidiol deficiency in haemodialysis patients?].

Maheut H, Chevriot F, Marty H, Lavaud S, Kazes I, Chanard J, Rieu P.

Nephrol Ther. 2009 Nov;5(6):542-9. doi: 10.1016/j.nephro.2009.05.002. Epub 2009 Jun 23. French.

PMID:
19553166
7.

Effect of membrane permeability on survival of hemodialysis patients.

Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R; Membrane Permeability Outcome (MPO) Study Group.

J Am Soc Nephrol. 2009 Mar;20(3):645-54. doi: 10.1681/ASN.2008060590. Epub 2008 Dec 17.

8.

Oral calcium load and fractional intestinal calcium absorption.

Drüeke TB, Chanard J.

Nephrol Dial Transplant. 2008 Oct;23(10):3368-9; author reply 3369-70. doi: 10.1093/ndt/gfn428. Epub 2008 Jul 31. No abstract available.

PMID:
18676348
9.

Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix.

Touré F, Zahm JM, Garnotel R, Lambert E, Bonnet N, Schmidt AM, Vitry F, Chanard J, Gillery P, Rieu P.

Biochem J. 2008 Dec 1;416(2):255-61. doi: 10.1042/BJ20080054.

PMID:
18643777
10.

[Anaphylaxis-like reactions in haemodialysis].

Chanard J.

Nephrol Ther. 2008 Oct;4(5):301-5. doi: 10.1016/j.nephro.2008.04.002. Epub 2008 Jun 2. French. No abstract available.

PMID:
18514605
11.

The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.

Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P.

Nephrol Dial Transplant. 2008 Jun;23(6):2003-9. Epub 2007 Dec 21.

PMID:
18156457
12.
13.

Anticoagulation in haemodialysis.

Chanard J, Lavaud S, Rieu P.

Nephrol Dial Transplant. 2006 Dec;21(12):3600-1; author reply 3601. No abstract available.

PMID:
17105823
14.

Renal replacement therapy in acute renal failure.

Chanard J, Wynckel A, Rieu P.

Lancet. 2006 Oct 28;368(9546):1491; author reply 1492. No abstract available.

PMID:
17071276
15.

Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors.

Molinaro G, Duan QL, Chagnon M, Moreau ME, Simon P, Clavel P, Lavaud S, Boileau G, Rouleau GA, Lepage Y, Adam A, Chanard J.

Kidney Int. 2006 Nov;70(10):1823-31. Epub 2006 Sep 27.

16.

A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.

Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, Rochefort D, Saint-Onge J, Flury L, Brown NJ, Gainer JV, Rouleau JL, Agostoni A, Cugno M, Simon P, Clavel P, Potier J, Wehbe B, Benarbia S, Marc-Aurele J, Chanard J, Foroud T, Adam A, Rouleau GA.

Am J Hum Genet. 2005 Oct;77(4):617-26. Epub 2005 Sep 1.

17.

Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.

Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, Birembaut P, Chanard J, Rieu P.

Am J Transplant. 2005 Oct;5(10):2441-7.

18.

Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration.

Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Chanard J.

ASAIO J. 2005 Jul-Aug;51(4):348-51.

PMID:
16156297
19.

Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies.

Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M.

ASAIO J. 2005 Jul-Aug;51(4):342-7.

PMID:
16156296
20.

Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.

Ureña Torres PA, Chanard J.

N Engl J Med. 2004 Jul 8;351(2):188-9; author reply 188-9. No abstract available.

PMID:
15250062

Supplemental Content

Loading ...
Support Center